A next-generation bioavailability platform

Disruptive Pharma is a Swedish pharmaceutical technology company focused on enabling better medicines through its proprietary Formulite^® platform for bioavailability enhancement and advanced drug formulation.

Formulite^® addresses key challenges in oral drug development by stabilizing drug molecules in an amorphous state to enhance solubility and bioavailability. This approach translates into several practical advantages for drug development and manufacturing:

• Optimized bioavailability: Through improved solubility and absorption
• Smaller pill size and reduced pill burden: Improved patient experience
• Cost-efficient manufacturing: Ideal for tableting and encapsulation
• Eco-friendly manufacturing process: Reduced solvent and polymer use

Business model

Our strategy supports the next phase of growth and commercialization, combining partnering-driven development with strategic collaborations with pharmaceutical companies, biotech companies and contract development and manufacturing organizations (CDMOs).

The business model is built around two main areas:

• Partnering and Development Agreements – formulation and product development projects for external partners, ranging from early feasibility assessments to advanced formulation development, product optimization, scale-up and support for lifecycle management programs.

• Platform Commercialization – strategic collaborations with CDMOs and other industrial partners to enable broader industrial use of Formulite^®.

Disruptive Pharma has also developed selected internal product candidates to generate data and demonstrate the applicability of the Formulite^® platform.

Improving drug products with Formulite

By leveraging our proprietary Formulite technology we can reformulate APIs to realize improved versions of selected products already on the market. The oral bioavailability of the API may be significantly enhanced by Formulite, resulting in a substantial API dose reduction with bioequivalent efficacy. This is expected to translate into lower inter-patient variability which also may improve API tolerability.

Drugs based on APIs with poor water solubility typically exhibit high efficacy levels, but patients suffer from an unfavorable side effect profile, such as a high rate of gastro-intestinal complications.

Enabling new chemical entities

Formulation of novel drug compounds may be challenging. The Formulite technology offers several solutions for small molecule drug delivery needs. It does not matter if the drug compound exhibits poor water solubility or is difficult to formulate for other reasons. We can tailor make the best solution, whether it is a new chemical entity (NCE) or an already known drug (API).

A drug compound loaded into Formulite can be directly filled into capsules. This means that one uniform Formulite formulation can be used in all pre-clinical studies, through the clinical program, and finally the commercial product. Through Formulite, formulation challenges are mitigated, the technical development risk is reduced and development time due to reformulation is kept at a minimum.